Drug Trial Radar · NCT06254482
An Extension Study to Evaluate the Long-Term Safety and Efficacy of Votoplam in Participants With Huntington's Disease (HD)
Last checked: Nov 20, 2026Latest source record: Nov 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
144
Actual
Start
Aug 25, 2023
Primary completion
Jul 16, 2029
Study completion Jul 16, 2029
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Feb 12, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 25 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary goal of this study is to evaluate the long-term safety and pharmacodynamic effects of votoplam in participants with HD.
Conditions
- Huntington Disease
Interventions
VotoplamDrug
Votoplam will be administered per dose and schedule specified in the arm.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Treatment-emergent Adverse Events (TEAEs)Time frame: Baseline up to Month 54
- Blood Total Huntingtin Protein (tHTT) LevelsTime frame: Baseline up to Month 52
Locations
24 sites in 10 countries. Site status is shown where the registry gives one.
Novartis Investigative Site
Clayton, Australia
Novartis Investigative Site
Westmead, Australia
Novartis Investigative Site
Innsbruck, Austria
Novartis Investigative Site
Ottawa, Canada
Novartis Investigative Site
Angers, France
Novartis Investigative Site
Marseille, France
Novartis Investigative Site
Paris, France
Novartis Investigative Site
Berlin, Germany
Novartis Investigative Site
Bochum, Germany
Novartis Investigative Site
Münster, Germany
Novartis Investigative Site
Ulm, Germany
Novartis Investigative Site
Bologna, Italy
Novartis Investigative Site
Milan, Italy
Novartis Investigative Site
San Giovanni Rotondo, Italy
Novartis Investigative Site
Leiden, Netherlands
Novartis Investigative Site
Christchurch, New Zealand
Novartis Investigative Site
Barakaldo, Spain
Novartis Investigative Site
Barcelona, Spain
Novartis Investigative Site
Burgos, Spain
Novartis Investigative Site
Madrid, Spain
Novartis Investigative Site
Birmingham, United Kingdom
Novartis Investigative Site
Cardiff, United Kingdom
Novartis Investigative Site
London, United Kingdom
Novartis Investigative Site
Manchester, United Kingdom
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.